


Cell Reports

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

Graphical Abstract



Authors

Tianli Xia, Hiroyasu Konno,
Jeonghyun Ahn, Glen N. Barber

Correspondence

gbarber@med.miami.edu

In Brief

Xia et al. provide evidence that STING is frequently functionally suppressed in human cancers, including colorectal cancer. Loss of STING prevented DNA-damage-mediated cytokine production, which renders tumor cells highly susceptible to DNA-oncovirus infection. Thus, STING activity is a crucial indicator of a patient's response to oncoviral therapy.

Highlights

- STING-dependent signaling is frequently suppressed in a variety of cancers
- Inhibition of STING signaling commonly involves silencing of the synthase cGAS
- DNA-damage-induced cytokine production is lost in STING-defective tumors
- Loss of STING function predicts the outcome of DNA-virus-mediated oncolytic activity

Accession Numbers

GSE75205



Xia et al., 2016, Cell Reports 14, 282–297
January 12, 2016 ©2016 The Authors
<http://dx.doi.org/10.1016/j.celrep.2015.12.029>

CellPress

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

Tianli Xia,¹ Hiroyasu Konno,¹ Jeonghyun Ahn,¹ and Glen N. Barber^{1,*}

¹Department of Cell Biology and the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA

*Correspondence: gbarber@med.miami.edu
<http://dx.doi.org/10.1016/j.celrep.2015.12.029>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

SUMMARY


Stimulator of interferon genes (STING) has been shown to be critical for controlling antiviral responses as well as anti-tumor adaptive immunity, but little is known regarding its regulation in human tumors. Here, we report that STING signaling is recurrently suppressed in a wide variety of cancers, including colorectal carcinoma. Loss of STING signaling impeded DNA damage responses accountable for generating key cytokines that facilitate tissue repair and anti-tumor T cell priming, such as type I interferons (IFNs). Correspondingly, defective STING function was also highly predictive of effectual DNA-virus-mediated oncolytic activity. Thus, impaired STING responses may enable damaged cells to evade host immunosurveillance processes, although they provide a critical prognostic measurement that could help predict the outcome of effective oncoviral therapy.

INTRODUCTION

Colorectal cancer (CRC) affects ~1.2 million people in the United States, and ~150,000 new cases are diagnosed every year. Indeed, CRC is the third most common cause of cancer worldwide, after lung and breast cancer, and the second leading cause of cancer death in adults (DeSantis et al., 2014). Intestine-associated malignant disease frequently develops from colonic epithelial cells that accumulate genetic alterations in key genes involved in the control of cell growth (Fearon, 2011). Multistep genomic-damage-aggravated alterations can be acquired from environmental factors comprising carcinogens or from genotoxic microbial pathogens, including *Helicobacter pylori* (Arthur et al., 2014; Dzutsev et al., 2015; Kim and Chang, 2014; Louis et al., 2014). Such genetic amendments frequently involve activation of cell growth signaling through mutation of *k-ras* as well as through mutation or epigenetic silencing of critical tumor suppressor genes (TSGs) such as p53 and adenomatous polyposis coli (*APC*). Mutated TSGs such as *APC* can also be inherited, thus increasing the risk of CRC significantly (Fearon, 2011; Hammoud et al., 2013).

Orally administered carcinogens such as the DNA-adduct-forming azoxymethane (AOM) induce genomic changes in gastrointestinal epithelial cells, an event that can trigger the activation of DNA damage response (DDR) pathways (Chen and Huang, 2009). While these responses involve repairing DNA breaks and eliminating base mismatches, they can also include activating the production of pro-inflammatory cytokines, which alerts the immune surveillance system to the damaged area and facilitates wound repair (Chatzinikolaou et al., 2014). For example, using murine models, it has been demonstrated that the administration of AOM followed by the inflammatory drug dextran sulfate sodium (DSS) can cause epithelial cells to produce IL-1 β and IL-18, which become processed by the inflammasome, a multiprotein complex comprising nucleotide-binding oligomerization-domain protein-like receptors (NLRs) such as NLRP3 and NLRP6, as well as apoptotic speck protein containing a CARD (ASC/PYCARD) and caspase-1, for secretion (Elinav et al., 2013). IL-18, for example, can bind to colonic dendritic cells and signal through MyD88 to prevent the production of growth-inhibitory IL-22 binding protein (IL-22BP), which enables unrestricted IL-22 to stimulate tissue repair (Huber et al., 2012; Salcedo et al., 2010). Thus, mice defective in key inflammasome-associated molecules such as ASC or caspase-1 are susceptible to carcinogen-induced colitis-associated cancer (CAC) (Elinav et al., 2013). Similarly, loss of key adaptor molecules such as MyD88, required for IL1-R signaling, makes mice more susceptible to AOM/DSS-induced CAC (Salcedo et al., 2013). Plausibly, unrepaired lesions enable the infiltration of microbes with heightened genotoxic aptitude that can chronically aggravate inflammatory processes and the production of DNA-damaging reactive oxygen species (ROS) (Arthur et al., 2012; Elinav et al., 2013).

Although the inflammasome has been shown to be important for processing proinflammatory cytokines such as IL-1 β and IL-18, it remained to be fully clarified how such wound repair proteins become transcriptionally activated in response to actual genomic damage. However, it has recently been shown that mice lacking the innate immune regulator STING (stimulator of interferon genes) are also sensitive to AOM/DSS-induced CAC (Ahn et al., 2015; Ishikawa and Barber, 2008). STING resides in the ER of hematopoietic cells as well as endothelial and epithelial cells and controls the induction of numerous host defense genes, such as type I IFNs, as well as pro-inflammatory genes, including IL-1 β , in response to the detection of cyclic



(legend on next page)

dinucleotides (CDNs), such as cyclic di-AMP (c-di-AMP), generated from intracellular bacteria (Burdette et al., 2011; Ishikawa et al., 2009). STING is also the sensor for CDNs produced from a cellular nucleotidyltransferase referred to as cGAS (cyclic GMP-AMP synthase, also referred to as Mab-21 domain-containing protein and C6orf150) (Sun et al., 2013). Cytosolic DNA species, which can constitute the genome of invading pathogens such as HSV-1, or plausibly self-DNA leaked from the nucleus, can bind to cGAS to generate non-canonical cyclic GMP-AMP (cGAMP) containing one 2'-5' phosphodiester linkage and a canonical 3'-5' linkage (c[G(2',5')pA(3',5')p]) (Hornung et al., 2014). The STING pathway may recognize damaged DNA during early response to intestinal damage and may be essential for invigorating tissue repair pathways involving IL-1 β and IL-18 (Ahn et al., 2014a, 2015). STING has also been recently reported to play an essential role in dendritic cell recognition of dying tumor cells and the priming of anti-tumor cytotoxic T cell (CTL) responses (Deng et al., 2014; Woo et al., 2014). Thus, while loss of STING may facilitate tumorigenesis by preventing wound repair and by preventing the production of tumor-specific CTLs, the effectiveness of STING signaling in human tumors remains unknown.

Here, we report that STING-mediated innate immune signaling is largely impaired in human colon cancers as well as many other types of human cancers. In many instances, this was achieved through silencing STING and/or synthase cGAS expression through epigenetic hypermethylation processes. Our findings suggest that the STING pathway may have a major function in suppressing colon tumorigenesis and that the inhibition of STING function in this pathway may be selectively suppressed during cancer development. However, we have found that defects in STING signaling render cancer cells more susceptible to oncolytic viral infection. Therefore, the examination of STING activity in cancers may lead to development of assays that will shed light on the outcome of select cancer therapies.

RESULTS

Defective STING Signaling in Colorectal Adenocarcinoma Cells

STING-deficient mice have been reported to be prone to AOM/DSS-associated CAC (Ahn et al., 2015). However, whether STING function is deregulated to any extent in human colorectal adenocarcinoma (CA) is unknown. To start to evaluate this, we examined STING expression by immunoblot in a variety of CA cells generated from cancers diagnosed at various stages as described using Duke's system (Wu, 2007). Results indicated

that STING was expressed in 10 out of 11 cell lines examined, albeit at varying levels (Figure 1A). To correlate expression levels with STING function, we transfected cells with double-stranded DNA (dsDNA) to activate STING signaling, or with dsRNA (poly(I:C)) to activate the RIG-I like pathway (Ishikawa and Barber, 2008). We then measured type I IFN expression by ELISA, which is known to be STING inducible. We noted that all 11 CA cells responded poorly to dsDNA-triggered type I IFN production. We confirmed that all cells were transfected adequately using fluorescein isothiocyanate (FITC)-labeled dsDNA activator and immunofluorescence analysis (Figure S1). This was in contrast to control hTERT cells or normal colon epithelial cells (FHC), which when transfected with dsDNA did express IFN- β (Figure 1B). In contrast, 8 of the 11 CA cells were able to produce type I IFN, in various amounts, in response to dsRNA, indicating that the RIG-I-like pathway retained function in the majority of cases examined (Figures 1B and S2A). A similar finding was noted upon examination of CXCL10 mRNA production by RT-PCR, although some CXCL10 was detected, albeit in low levels, in LoVo and HT29 in response to STING-dependent dsDNA transfection (Figure 1C), whereas poly(I:C) induced CXCL10 production in majority of CA cells at varying degrees (Figure S2B). To extend these findings further, we measured IL-1 β production in the CA cells, since we have previously noted that carcinogen-triggered DNA damage can induce IL-1 β through STING signaling (Ahn et al., 2012). Loss of IL-1 β has been shown to render mice susceptible to CAC due to impairment of wound-healing responses (Elinav et al., 2013). This study indicated that IL-1 β was produced in normal hTERT and FHC cells by dsDNA, indicating the importance of STING activity in this process. However, only 3 out of the 11 CA cells appeared able to produce IL-1 β in response to dsDNA treatment, again suggesting that STING function is defective in the majority of CA cells examined (Figure 1D). SW48, which lacked STING expression, did not appear responsive to dsDNA transfection in any capacity. RNAi treatment confirmed that the upregulation of these cytokines was STING-dependent (Figures S3A–S3C). Given these data, we performed a more detailed analysis of dsDNA-dependent STING signaling in CA cells using microarray analysis. CA cells were selected based on their ability to exhibit some STING function or not. For example, data from Figure 1C indicated that HT29 and LoVo cells were partially able to produce CXCL10 in response to dsDNA. In contrast, SW480 and HT116 were noted to be unable to produce CXCL10 to any significant level. Microarray analysis revealed that all the CA cells examined did not respond to dsDNA signaling as efficiently as control FHC cells and confirmed our RT-PCR analysis (Figures 1E and 1F).

Figure 1. STING-Mediated dsDNA-Induced Innate Immune Activation Is Impaired in the Majority of Human Colon Cancer Cell Lines

(A) Immunoblot of STING in hTERT fibroblasts and normal human colon epithelial (FHC) and a series of human colon cancer cell lines.
(B) ELISA analysis of human IFN- β production in the media of cells (same as in A) transfected with 3 μ g/ml poly(I:C) or dsDNA90 or mock transfected for 16 hr.
(C) qPCR analysis of human CXCL10 expression in cells (same as in A) transfected with 3 μ g/ml dsDNA90 or mock transfected for 3 hr.
(D) qPCR analysis of human IL1 β expression in cells (same as in C). Data are representative of at least two independent experiments. Error bars indicate SD. *p < 0.05, **p < 0.01, and ***p < 0.001; Student's t test.
(E) Microarray analysis of gene expression in indicated normal and colon cancer cells mock transfected or transfected with 3 μ g/ml dsDNA90 for 3 hr. Highest-variable genes are shown. Rows represent individual genes; columns represent individual samples. Pseudocolors indicate transcript levels below (green), equal to (black), or above (red) the mean. Scale represents the intensity of gene expression (log10 scale ranges between -3 and 3).
(F) Fold-change values of the highest-variable genes shown in (E).
See also Figures S1 and S2.

For instance, the level of CXCL10 was significantly higher in the control FHC cells compared to the CA cells analyzed. However, HT29 cells did appear to be able to retain some response to cytosolic dsDNA, more than any of the other CA cells examined, especially when compared to SW480 or HT116 (Figures 1E and 1F). While HT29 was able to produce IFN- β moderately as determined by microarray analysis, IFN- β protein production was not readily evident by ELISA, perhaps due to low-level expression, which was similarly observed even in the FHC controls (Figure 1B). Nevertheless, taken together, our data indicate that a majority of CA cells exhibit defective STING-dependent signaling, with only SW1116, LS123, LoVo, and HT29 exhibiting some low-level STING activity.

Loss of IRF3 Function in CA Cells

To examine the extent of defective STING signaling in CA cells, we performed immunofluorescence and immunoblot analysis to evaluate NF- κ B and IRF3 function. In the presence of dsDNA, STING rapidly undergoes trafficking from the ER, along with TBK1, to perinuclear-associated endosomal regions, containing NF- κ B and IRF3, in a process resembling autophagy (Ishikawa and Barber, 2008; Konno et al., 2013). This event accompanies STING phosphorylation and degradation, likely to avoid sustained STING-activated cytokine production, which can manifest inflammation (Ahn and Barber, 2014). This approach confirmed that STING could traffic and undergo phosphorylation and degradation in the control hTERT and FHC cells, following treatment with dsDNA (Figures 2A and 2D, left). In these cells, TBK1 became phosphorylated as well as its cognate target IRF3 and the p65 subunit of NF- κ B (Figure 2D, left). IRF3 and p65 were also noted to translocate into the nucleus, as expected (Figures 2B and 2C). A comparable effect was observed using SW1116 and LS123 CA cells, which exhibited modest dsDNA-dependent IL-1 β induction, confirming that the STING pathway retained some function in these two cells (Figures 2A–2D, 1C, and 1D). However, while HT29 and LoVo displayed similar IRF3 translocation, these cells lacked p65 translocation. This likely helped to explain that the defect in dsDNA-mediated innate immune gene induction rested in the inability of STING to trigger p65 function (Figures 2A–2D, 1E, and 1F). In addition, we noted that the other CA cells, such as SW480, SW1417, SW48, and HT116, exhibited very little STING activity or trafficking (Figures 2A and 2D right). Similarly, little evidence of TBK1 or IRF3 phosphorylation/translocation was noted (highlighted by red boxes). Some indication of p65 phosphorylation was revealed, for example in SW480, but translocation of this transcription factor was not evident in any of the LoVo, HT29, SW480, SW48, SW1417, or HT116 cells. In contrast, dsRNA induced IRF3 translocation in majority of CA cells, although p65 translocation seemed to be impaired to a larger extent (Figures S2C and S2D). STING expression was not observed in SW48 cells as previously described (Figures 1A, 2A, and 2D). These data indicate that dsDNA signaling is affected at various points of the STING pathway. For example, STING retains some activity and ability to traffic and escort TBK1 to IRF3, as in HT29 or LoVo cells, but NF- κ B signaling is affected. In contrast, STING does not appear to undergo any phosphorylation or trafficking in SW480, SW1417,

SW48, or HT116 cells, suggesting that STING function is impeded upstream of IRF3/NF- κ B interaction.

CA Cells Exhibit Defective cGAS Expression

Loss of STING trafficking in SW480, SW1417, SW48, or HT116 cells could indicate a problem with STING function in the ER, perhaps involving a mutation that would render STING unable to interact with CDNs. Conversely, the breakdown in STING signaling could occur upstream and involve the synthase cGAS, which can generate CDNs following association with dsDNA, to augment STING function (Konno et al., 2013). To evaluate this, we sequenced the entire STING genome within all 11 CA cells (introns and exons comprise \sim 7.2 kb on chromosome 5q31.2). Sequence analysis indicated that 2 of the 11 CA cells (LoVo and SW480) exhibited a previously reported HAQ STING variant (Jin et al., 2011; Yi et al., 2013), which occurs in \sim 20% of the population, and which has been reported to be partially defective when overexpressed in 293T cells, yet is able to function normally in the presence of CDNs (Table S1). The remainder of the *STING* genes analyzed represented the R272 encoded product, which has not been reported to exert any defects in function and which represents \sim 85% of the population. Collectively, these findings do not suggest the existence of a major mutation in the *STING* gene contained within the CA cells and suggest that a defect upstream of STING, for example at the level of cGAS, could plausibly be prevalent. We thus started to examine the expression and activity of cGAS in CA cells. We developed an RT-PCR assay and principally measured cGAS mRNA levels. Our results indicated that, of the 11 CA cells examined, cGAS expression was absent in 5 (45%) of them (LS174T, SW480, SW1417, SW48 and HT116) (Figure 3A). These data were confirmed via immunoblot and immunohistochemistry analysis using an antibody to cGAS (Figure 3A). A qPCR examination of 48 human colon adenocarcinoma samples similarly indicated low to undetectable level of cGAS in 15 of 48 samples (31%) (Figure S4). Our findings could be explained through loss of the cGAS gene. However, sequencing analysis similarly indicated that no major mutations or deletions existed within the genome encoding the cGAS gene (Table S2). In view of this, we examined whether cGAS expression was suppressed by epigenetic phenomena, such as by hypermethylation of the cGAS promoter region (Lao and Grady, 2011; Mitchell et al., 2014). Indeed, databank analysis indicated the presence of considerable CpG islands within the cGAS promoter region (Figure S5A). Control hTERT or cGAS-defective LS174T, SW480, SW1417, SW48, or HT116 cells were thus treated with the demethylating agent 5-aza-2'-deoxycytidine (5AZADC) for 5 days, and cGAS mRNA levels were again evaluated. Our study indicated that cGAS expression was rescued in two of the five cells examined (SW480 and HT116) (Figure 3B). The sequencing of bisulfite converted genomic DNA retrieved from normal and CA cells confirmed significant hypermethylation within the cGAS promoter region of CA cells where cGAS expression is suppressed (Figure S5B). It is not yet clear why expression levels of cGAS are muted in the remainder of the CA cells (LS174T, SW1417, and SW48), but suppression could speculatively involve other epigenetic modifications such as histone modifications (Jin and Robertson, 2013). Accordingly, treatment of these cells with histone




Figure 2. The dsDNA-Induced STING Signaling Pathway Is Defective in the Majority of Human Colon Cancer Cell Lines

(A) Immunofluorescence microscopy analysis of STING translocation in normal and human colon cancer cell lines transfected with 3 μg/ml dsDNA90 or mock transfected for 3 hr.

(B) Immunofluorescence microscopy analysis of IRF3 translocation in cells (same as in A).

(C) Immunofluorescence microscopy analysis of p65 translocation in cells (same as in A). Representative images are shown at original magnification 1,260×. Scale bar, 1 μm.

(D) Immunoblot analysis of STING signal activation in cells (same as above) transfected with 3 μg/ml dsDNA90 for the indicated time periods.




Figure 3. cGAS Expression Is Suppressed in Many Human Colon Cancer Cell Lines and Can Be Partially Recapitulated through DNA Demethylation

(A) Immunoblot (top) and qPCR analysis (bottom) of cGAS expression in normal and human colon cancer cells.

(legend continued on next page)

deacetylase or histone-lysine methyltransferases inhibitors partially rescued cGAS mRNA expression in CA cells examined (LS174T, SW1417, and SW48) (Figure S5C). It may also be apparent that alternate mechanisms of cGAS suppression exist, such as those involving microRNAs (miRNAs) (Yarbrough et al., 2014). To determine if reconstitution of cGAS expression rescued STING-dependent dsDNA signaling, we examined control hTERT or SW480, HT116 (cGAS rescued by 5AZADC), or LS174T (cGAS not rescued by 5AZADC) CA cells. We observed that the 5AZADC-treated cGAS-rescued SW480, HT116 CA cells, but not LS174T cells, regained phosphorylation of TBK1 and IRF3, with concomitant phospho-IRF3 translocation (Figures 3C and 3D). These effects were reflected in modest expression of type I IFN and IL-1 β in the 5AZADC-treated SW480 and HT116 CA cells (Figures S5D and S5E). Thus, demethylating agents may be able to partially rescue STING-dependent innate immune gene induction in select CAs.

The question arises as to why the STING-signaling pathway may be inhibited in colon adenocarcinoma. Recently, we have shown that STING-deficient cells and mice are sensitive to AOM-induced DNA damage (Ahn et al., 2015). In this situation, the STING pathway may play a role in the DNA damage response pathway by inducing the production of cytokines that facilitate tissue repair or damaged cell removal (Chatzinikolaou et al., 2014; Kidane et al., 2014; Lord and Ashworth, 2012). We thus examined innate immune induction of CA cells in response to DNA-damaging agents. As shown in Figure 3E, the carcinogens AOM and DMH (1,2-Dimethylhydrazine) were able to induce the production of type I IFN in normal colon epithelial (CCD841) and in LS123 (which exhibited partial STING activity; Figures 1C and 1D). However, CA cells that exhibited defective STING-activated IRF3 or NF- κ B activity were unable to generate type I IFN in response to AOM or DMH (Figure 3E). Thus, the inhibition of the STING pathway may enable DNA-damaged cells, harboring mutations, to escape part of the DNA damage response and the immune surveillance machinery to progress into a tumorigenic state.

Tumors with Defective STING-Signaling Are Sensitive to Viral Oncolysis

We have previously shown that loss of STING signaling in vitro or in vivo renders cells or mice, respectively, extremely sensitive to herpes simplex virus (HSV) infection (Ishikawa and Barber, 2008; Ishikawa et al., 2009). HSV, containing a dsDNA genome of 375 kb, is presently being evaluated in clinical trials as a therapeutic agent for the treatment of cancer (Kolodkin-Gal et al., 2009). However, the mechanisms of oncolysis remain to be fully determined, and there is no evaluation, presently, for determining the efficacy of HSV antitumor treatment. Given that we have previously shown that STING signaling plays a critical role in host de-

fense responses to HSV infection, and that STING activity is defective in numerous CA cells, we postulated that the ability of STING to signal may affect outcome to HSV oncoviral therapy. To start to address this, we infected the CA cells or control hTERT and FHC with HSV1 lacking the γ 34.5-encoding product that is presently being evaluated as an oncolytic agent, including against colon cancer as well as melanoma. The γ 34.5 viral protein has been proposed to suppress host defense responses, although the mechanisms remain to be fully clarified. Thus, HSV1 γ 34.5 does not robustly repress innate immune signaling events and potentially triggers STING-dependent innate immune gene induction, including type I IFNs (Ishikawa et al., 2009). This analysis indicated that similar to our dsDNA transfection results, HSV1 γ 34.5 induced the production of IFN β mRNA significantly in control hTERT and FHC cells, as well as SW1116 and LS123 CA cells (Figure 4A). However, little type I IFN was induced in the remainder of the CA cells, including SW480 and HT116, deficient in cGAS expression. The ability to induce type I IFN inversely correlated with HSV1 γ 34.5 replication, due to the induced antiviral effects (Figure 4B). Furthermore, cells such as SW480 and HT116 underwent rapid cell death, likely due to robust viral replication, while control cells and cells with partial STING function (SW1116 and HT29) were significantly more refractory (Figure 4C). We followed up by infecting CA cells with HSV expressing the luciferase gene that contained γ 34.5 (HSV-Luc). These data confirmed that CA cells exhibiting defective STING-signaling such as SW480 and HT116 enabled more viral-induced luciferase expression (Figure 4D). Small interfering RNA (siRNA) treatment further confirmed that the IFN- β responses induced by HSV1 γ 34.5 in normal and STING functional CA cells are STING dependent (Figure S3D). Of note is that HSV1 is not the only DNA virus to be considered as an oncolytic therapeutic agent to treat cancer. Other candidate viruses under consideration, including as a therapeutic against colon cancer, comprise vaccinia virus (VV), a dsDNA virus with a 190-kb genome that replicates in the cytoplasm of infected cells (Rowe and Cen, 2014). To evaluate whether VV can trigger host innate immune response in the absence of functional STING signaling, we infected CA cells with partial STING signaling capacity (SW1116 and HT29) or completely defective STING signaling (SW480, HT116) with VV. Similar to the situation using HSV1 γ 34.5, VV triggered type I IFN and CXCL10 production only in the control cells or CA cells with partial STING signaling ability and not in cells with loss of STING function (SW480 and HT116) (Figures 4E and 4F). We further analyzed CA cell susceptibility of VV infection. As shown in Figures S6A–S6D, increased VV replication and cell death were observed in all cells exhibiting loss of cGAS or STING. Our data indicate that CA cells with defective STING-signaling are highly susceptible to HSV1 and

(B) qPCR analysis of cGAS expression in cGAS-negative colon cell lines mock treated or treated with 1 μ M 5-azacytidine (5AZADC) for 5 days. Data are representative of at least two independent experiments. Error bars indicate SD. * p < 0.05, ** p < 0.01, and *** p < 0.001; Student's t test.

(C) Immunoblot analysis of STING signal activation in cells (selected from B) mock treated or treated with 1 μ M 5-azacytidine (5AZADC) for 5 days, followed by dsDNA90 transfection at 3 μ g/ml for the indicated time periods.

(D) Immunofluorescence microscopy analysis of IRF3 translocation in SW480 and HT116 cells treated with 5AZADC (same as above) followed by dsDNA transfection at 3 μ g/ml dsDNA90 for 3 hr. Representative images are shown at original magnification 1,260 \times . Scale bar, 500 nm.

(E) Normal and colon cancer cells were treated with AOM or DMH at 3 mM for 20 hr. IFN β induction was analyzed by qPCR analysis.

See also Figures S3 and S4.




Figure 4. STING Signal Defect Leads Colon Cancer Cells More Susceptible to DNA Virus Infection

(A) Cells (same as in Figure 1) were infected with HSV1γ34.5 at MOI 5 for 1 hr, and human *IFNβ* induction was analyzed by qPCR 3 hr post-infection.

(B) Normal human hTERT cells and selected human colon cancer cell lines (cGAS positive: SW1116, HT29; cGAS negative: SW480, HT116) were infected with HSV1γ34.5 at the indicated MOI for 1 hr, and titration of HSV1γ34.5 was analyzed by standard plaque assay in Vero cells 24 hr later.

(C) Cells (same as in B) were infected with HSV1γ34.5 at MOI 1 for 1 hr, and cell viability was analyzed by trypan blue staining 24 hr and 48 hr later.

(D) Cells (same as in A) were infected with HSV1-Luc at the indicated MOI for 1 hr, and luciferase activity was analyzed 24 hr later.

(E) Colon cancer cells were infected with vaccinia virus at MOI 100 and analyzed by qPCR for *IFNβ* expression 3 hr postinfection.

(F) Cells (same as in E) were analyzed by qPCR for *CXCL10* expression.

Data are representative of at least two independent experiments. Error bars indicate SD. **p* < 0.05 and ***p* < 0.01; Student's *t* test. See also Figure S2.

VV oncolytic activity. Thus, it is plausible that being able to measure the presence or absence of STING/cGAS expression may help predict the response of patients with certain cancers to selected viral oncolytic therapy.

Predicting Outcome to Viral Oncolytic Therapy

Our data indicate that the outcome of oncolytic virotherapy involving DNA-based viruses such as HSV1 may be predicted by the presence or absence of STING signaling. Since the STING pathway naturally requires the presence of STING and cGAS to function, and since we have observed that STING and/or cGAS may be absent in 30%–55% of colon cancers, being able to measure the presence of these two gene products may therefore indicate the effectiveness of DNA-viral oncotherapy. This could be achieved using RT-PCR methodology, but biopsied tissue may contain infiltrating hematopoietic cells that contain nor-

mal STING/cGAS expression (Ishikawa et al., 2009). Thus, analysis of STING and/or cGAS protein or RNA expression within the cancer cell itself would provide more accurate information into the status of STING function. First, we designed a RNA in situ hybridization assay using RNAscope technology that can detect the single levels copies of an mRNA within individual cells. By labeling the STING probe green (FITC), and the cGAS probe red (Cy5), we were able to use both probes in the same assay and effectively quantitate the mRNA levels of

STING and cGAS within the identical cell. To test the assay, we incubated control cells or cGAS-positive (SW1116 or HT29) or negative (SW480 and HT116) CA cells with RNA probes recognizing cGAS (red) or STING (green) mRNA. This study indicated that STING and cGAS expression could be detected and quantitated in the control (hTERT and FHC) and STING/cGAS-positive (SW1116 or HT29) CA cells using the RNAscope (Figures 5A and 5C). However, only STING was observed in the cGAS-negative (SW480 and HT116) CA cells (Figures 5A and 5C). STING was not detectable in SW48 cells, as expected, using this assay (Figures 1A, 5A, and 5C). These data also correlated with our previous expression analysis of cGAS in these cells by RT-PCR (Figure 3A). Moreover, we were able to observe cGAS expression by RNAscope in those CA cells where cGAS mRNA production was rescued following treatment with 5AZADC (SW480 and HT116) (Figures 5B and 5D). Thus, fluorescence

in situ hybridization analysis may be able to predict the outcome to oncolytic viral therapy depending on the presence or absence of cGAS or STING.

To further follow up on this assay, we paraffin embedded normal hTERT or cGAS-positive (SW1116 or HT29) or negative (SW480 and HT116) CA cells. We also analyzed SW48, in which both cGAS and STING expression was missing. This situation may mimic situations where biopsied and paraffin embedded patient derived material required analysis. We were again readily able to detect using the RNA probes both STING and cGAS expression in control, SW1116, and HT29 cells, as before, and only STING in the cGAS-negative SW480 and HT116 CA cells (Figures 5E and 5F). Neither cGAS nor STING was observed in the double-negative SW48 line (Figures 1A, 5E, and 5F). Using antibody to cGAS and STING, we also performed immunohistochemistry (IHC) analysis on paraffin-embedded cells and confirmed cGAS and STING expression, or not, in accord with our immunoblot and RNAscope studies (Figures 1A, 3A, 5A, 5F, and 5G). Subsequently, we further tested our RNAscope assay on 12 normal and 80 CA samples in paraffin-embedded tissue microarrays (TMAs) and observed substantial loss of *STING* and *cGAS* RNA expression starting from stage II. Overall, 36% (29 out of 80) cancer samples had undetectable *STING* and/or *cGAS* RNA in stage II–IV colon cancer (Figures 6A and 6B). Furthermore, IHC analysis of a human colon cancer TMA corroborated our RNA analysis and similarly showed substantial loss of STING and/or cGAS protein expression starting predominantly in stage II samples, generating an overall (stage II–IV) of 54% loss (21 out of 39) (Figures 6C and 6D). Statistical analysis of STING and cGAS expression in different stages of colon cancer using the H-score method showed significant loss of cGAS expression by IHC as early as stage II, whereas loss of STING is more profound in later stages (Table S3). Given these data, it is plausible that STING/cGAS expression is also lost in other tumor types. Subsequently, we indeed noted that STING expression and/or function was absent in a variety of other tumor types, indicating that suppression of this pathway may be widespread in human cancer (Figure S7). In summary, RNAscope and IHC procedures may be useful for the analysis of cGAS and STING expression in formalin-fixed paraffin-embedded (FFPE) preserved samples.

In Vivo Analysis of CA Cells with Defective STING Signaling to HSV1 γ 34.5 Therapy

It is possible that loss of STING signaling may affect the outcome to select oncoviral therapy (Figures 4A–4D) (Kolodkin-Gal et al., 2009; Rowe and Cen, 2014). To start to evaluate this in vivo, we correlated the in vitro oncolytic effect of HSV1 by subcutaneously inoculating nude mice with CA cells harboring partial (SW1116 or HT29) or defective (SW480 and HT116) STING signaling. HSV1 γ 34.5 was then administered intratumorally and tumor growth monitored (Figure 7A). This study indicated that tumors exhibiting partial STING signaling (SW1116 and HT29) were refractory to viral oncolytic treatment (Figures 7B and 7C). While these tumors had different growth rates in vivo, they did not significantly respond to viral therapy, and the mice were sacrificed after the tumor burden became significant. In contrast, tumors derived from CA cells with defective STING

signaling (SW480 and HT116) were noted to be extremely susceptible to virus treatment (Figures 7D and 7E). In mice implanted with SW480, tumor size decreased rapidly 3 days after HSV1 γ 34.5 treatment, and four out of seven tumors diminished 2–3 weeks after treatment (Figure 7D). In addition, we examined the oncolytic effect of vaccinia virus in CA cells exhibiting partial STING signaling (HT29) or completely defective in STING signaling (HT116), and we observed that vaccinia virus reduced the growth of HT116 in nude mice significantly ($p = 0.012$) when compared to HT29 ($p = 0.297$) (Figures S6E and S6F). Our data thus correlate with our in vitro findings and indicate that the activity of the STING pathway may predict the outcome of DNA virus-related oncolytic therapy against colon and perhaps other cancers.

DISCUSSION

The STING-controlled signaling pathway is essential for facilitating innate immune gene transcription in response to the recognition of cytosolic DNA species (Ishikawa and Barber, 2008). STING activity can be triggered by CDNs such as cyclic di-AMP or cyclic di-GMP produced from intracellular bacteria such as *Listeria monocytogenes* or by cyclic di-GMP-AMP (cGAMP) manufactured by the synthase cGAS following association with cytosolic dsDNA species (Burdette et al., 2011; Cai et al., 2014). Such DNA can represent the genome of DNA pathogens, such as HSV-1 or bacteria such as mycobacterium tuberculosis, as well as self-DNA leaked from the nucleus of DNA-damaged cells. STING-deficient mice, while viable, are extremely sensitive to lethal infection by a variety of pathogens (Ishikawa et al., 2009). However, chronic STING activity has been shown to cause a diversity of autoinflammatory disease, through the overproduction of pro-inflammatory cytokines (Ahn and Barber, 2014). Indeed, inappropriate overstimulation of STING has even been shown to aggravate inflammation driven skin cancer (Ahn et al., 2014b). Recently, transient STING activity has been shown to be essential for mediating the generation of anti-tumor T cell responses (Woo et al., 2015). Data suggest that STING, in professional antigen-presenting cells (CD8⁺ dendritic cells), becomes extrinsically activated by the DNA of engulfed dying tumor cells, which results in the triggering of cytokines such as type I IFNs, which facilitates cross-presentation and CTL priming (Woo et al., 2014). Correspondingly, the therapeutic administration of CDNs, intratumorally, has been shown to repress tumor growth, presumably by facilitating dendritic cell-dependent CTL production (Corrales et al., 2015; Woo et al., 2014). STING may also play a role in influencing the anti-tumor effects of checkpoint inhibitors such as PD1, although the mechanisms remain to be determined (Fu et al., 2015).

We have also recently demonstrated that STING-deficient mice are susceptible to carcinogen-aggravated CAC; however, STING-deficient cells are not highly susceptible to oncogenic transformation (Ahn et al., 2015). In this situation, evidence indicates that damaged DNA can trigger STING-intrinsic activity, perhaps by leaking out of the nucleus or through other mechanisms that remain to be clarified. Presumably, this event would augment cytokine production that would attract the immune system to the damaged cells (Ahn et al., 2014a,




Figure 5. RNA In Situ Hybridization and Immunohistochemistry Analysis of STING and cGAS in Human Colon Cancer Cell Lines

(A) RNA fluorescence in situ hybridization (RNA FISH) analysis of STING and cGAS expression in normal and human colon cancer cell lines. Representative images are shown at 1,260 \times . Scale bar, 500 nm.

(legend continued on next page)

2014b; Chatzinikolaou et al., 2014; Deng et al., 2014; Kidane et al., 2014; Zhu et al., 2014). Eradication of such cells may ensue, as well as the stimulation of cytokine- and growth-factor-dependent tissue repair. Data suggest that STING can trigger the production of cytokines that facilitate wound repair in the gut, such as IL-1 β . Such cytokines are processed by nucleotide-binding oligomerization-domain protein-like receptors (NLRs) such as NLRP3 and NLRP6, which interact with inflammasome-associated ASC and caspase-1 to process IL-1 β and IL-18 (Elinav et al., 2013). These pro-inflammatory cytokines are secreted and bind to receptors mainly requiring MyD88 for signaling. IL-18 production can suppress IL-22BP, which is responsible for inhibiting the wound-repair activity of IL-22 (Huber et al., 2012). Loss of ASC, caspase-1, MyD88, or IL22BP can increase tumorigenesis in colitis-associated colon cancer models, similar to loss of STING (Barker et al., 2011; Elinav et al., 2013; Huber et al., 2012; Salcedo et al., 2010). STING may therefore work in concert with inflammasome processing.

Thus, loss of STING suppresses tissue healing, and damaged mucosal lining may enable the invasion and expansion of bacteria with enhanced genotoxic ability, which would aggravate STING-independent inflammatory responses (Ahn et al., 2015; Arthur et al., 2012). The generation of ROS by overactive, infiltrating immune cells may enhance DNA-damaging processes and facilitate mutational inactivation of TSGs or the mutational activation of growth stimulatory proteins such as *k-ras* (Fearon, 2011; Sosa et al., 2013). Thus, intrinsic STING signaling may play a key role in preventing the development of cancer through responding to DNA damage and alerting the immune surveillance machinery (Chatzinikolaou et al., 2014; Kondo et al., 2013). In addition, extrinsic STING activity in dendritic cells is also required for the generation of anti-tumor CTLs (Corrales et al., 2015; Woo et al., 2015). This places STING in a pivotal role in the host anti-cancer defense arsenal in which intrinsic STING activity facilitates clearance of pre-cancerous cells by alerting the immune system and extrinsic STING signaling stimulates anti-tumor T cell activity.

Given this, we analyzed the expression and regulation of STING signaling in colon cancer and found frequent suppression of STING activity. These events inhibited the production of DNA-damage-dependent cytokine production, which may enable the damaged cell to escape the attention of the immune surveillance system. Such cells may evade eradication and further genetic mutation events may accrue to enhance the tumorigenic process (Elinav et al., 2013; Kidane et al., 2014). The inhibition of STING signaling was observed to mainly involve the suppression of STING expression or of the synthase cGAS. We did not observe significant mutation or deletion events involving the *STING* or

cGAS genes but rather observed frequent transcriptional suppression involving hypermethylation of the promoter regions. We were able to partially rescue cytosolic DNA signaling using demethylating agents, which regained cGAS expression in some, but not other, CA cells. However, it remains unclear whether the rescue of STING signaling in cancer cells may afford better responses to anticancer agents. Further, that cGAS and in some cases STING expression was not rescued by demethylating agents may indicate other forms of epigenetic silencing that requires additional characterization. In other CA types, we observed that the ability of STING to activate the transcription factors NF- κ B or IRF3 was impaired, by molecular mechanisms that also remain to be determined. It is noteworthy that a number of other genes involved in DNA repair, such as the mismatch repair proteins MSH2 and MLH1 are also reported to be frequently silenced in colon cancer (Chatzinikolaou et al., 2014; Le et al., 2015; Lord and Ashworth, 2012). Thus, targeting the DNA repair machinery maybe a common requirement in cancer development. Collectively, we observed that STING-dependent signaling was defective in numerous colon related tumors examined. This may indicate that suppression of STING function is also a key obligation for the tumorigenic process.

Since loss of STING may be common in tumors and may even predict outcome to anticancer therapy, we also developed assays to evaluate the expression levels of both STING and cGAS. Loss of either of these two proteins appears to repress cytosolic DNA-mediated innate immune signaling. Our ability to measure *STING* and cGAS mRNA expression in situ and STING protein expression using antibody enabled us to develop a screen that indicated loss of one or other of these proteins in over 40% of CAC. Such assays may be useful in predicting the effective response rates of cancers to select therapeutic interventions. Further, recapitulating STING signaling in tumors, via novel antitumor gene therapy approaches, might enable such cells to reactivate host antitumor immunity.

Accordingly, we noticed that loss of STING signaling in CA cells enabled the robust replication of DNA-based viruses such as HSV1. Viruses such as HSV1 and vaccinia virus are presently being used as oncolytic agents for the treatment of cancer (Klodkin-Gal et al., 2009; Rowe and Cen, 2014). Such viruses may directly destroy the tumor cell by lysis as well as create a tumor antigen source for engulfment by APCs for the generation of CTLs (Woo et al., 2015). Data indicate that STING plays a key role in both of these processes (Figure S8). However, the efficacy of successful oncoviral therapy remains low for reasons that remain unclear. Mainly, assays based on molecular insight that may help predict treatment outcome have not been developed. This is because the molecular mechanisms that explain

(B) RNA FISH analysis of STING and cGAS expression in SW480 and HT116 mock treated or treated with 1 μ M 5 AZADC for 5 days. Representative images are shown at 1,260 \times . Scale bar, 500 nm.

(C) Quantitation of *STING* and cGAS RNA copy number in (A).

(D) Quantitation of cGAS RNA copy number in (B).

(E) STING and cGAS expression in formalin-fixed paraffin-embedded (FFPE) normal and human colon cancer cell lines was analyzed by chromogenic RNA in situ hybridization (RNA CISH). Quantitation of *STING* and cGAS RNA copy number are shown in bar graph. Data are representative of at least two independent experiments. Error bars indicate SD. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$; Student's t test.

(F) Representative images of STING and cGAS RNA CISH analysis are shown at 600 \times . Scale bar, 1 μ m.

(G) Immunohistochemistry analysis of cGAS and STING expression in colon cancer cells. Images are shown at 400 \times . Scale bar, 20 μ m.




Figure 6. RNA In Situ Hybridization Analysis in Colon Cancer Tissue Microarray

(A) RNA CISH analysis of STING and cGAS expression in a human colon cancer TMA. STING and/or cGAS expression status in each tissue is summarized in the table.

(B) Representative images in (A) are shown at 400 \times . Scale bar, 20 μ m.

(C) IHC analysis of STING or cGAS expression in a human colon cancer TMA. Expression status is summarized in the table.

(D) Representative images in (C) are shown at 200 \times . Scale bar, 50 μ m.

See also Figure S5.




Figure 7. Increased HSV1 γ 34.5 Oncolytic Effect Was Observed in Colon Cancer Cells with Impaired STING Signal In Vivo

(A) Scheme of HSV1 γ 34.5 treatment on a xenograft tumor in nude mice.

(B–D) The indicated xenograft tumors were generated in the right flank of nude BALB/c mice. When tumors reached ~0.5 cm in diameter, they were injected every other day, for a total of three times (arrows), with 1E7 PFU HSV1 γ 34.5 in 50 μ l PBS (n = 7) or 50 μ l PBS only (n = 3), and tumor growth was measured every other day. Data are representative of two independent experiments. Statistical analysis was carried out comparing the two treatment groups at the last time point using the unpaired Student's t test. p values are as indicated.

oncolysis in cancer cells rather than normal cells remains to be fully appraised. Evidence suggests that innate immune signaling pathways that exert antiviral activity may be defective in cancer cells (Heiber and Barber, 2012). In a tumor cell, functional intrinsic STING signaling would prevent efficient virus replication and oncolysis. We propose that this impedes the effectiveness of oncolytic activity. However, in cells lacking STING, greater oncolytic activity is expected and indeed observed and greater cytolysis occurs, as our data show. This would provide a larger amount of tumor cell lysate that would be engulfed and cross-presented for T cell priming (which requires STING). Our data presented here are among the first clear indication that loss of an innate signaling pathway can predict outcome to oncoviral therapy. Thus, utilization of molecular biomarker assays similar to the ones portrayed here may enable a more predictive response to the use of microbes for the treatment of cancer. Such assays may also shed insight into whether other STING-dependent anti-tumor therapies based on CDNs, or even DNA-adduct based chemotherapeutic regimens, may work or not (Zitvogel et al., 2013). In this light, we have recently described that the immunological benefits of using chemotherapeutic agents such as cisplatin and etoposide significantly involved the STING-signaling pathway (Ahn et al., 2014b). Thus, further studies on the regulation and function of STING in cancer may provide acumen into the molecular mechanisms of tumorigenesis as well as provide a therapeutic target that may help in the treatment of cancer.

EXPERIMENTAL PROCEDURES

Materials

All reagents were from Invitrogen, Thermo Scientific, or Sigma-Aldrich unless otherwise specified.

Cell Culture

Cells were purchased from Lanza and ATCC and cultured in their appropriate growth media. hTERT-BJ1 telomerase fibroblasts (hTERT) were originally from Clontech and cultured in 4:1 ratio of DMEM:Medium 199 supplemented with 10% fetal bovine serum, 4 mM L-glutamine, and 1 mM sodium pyruvate at 37°C in a 5% CO₂-humidified atmosphere.

Immunoblot Analysis

Equal amounts of proteins were resolved on SDS-polyacrylamide gels and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). After blocking with 5% blocking reagent, membranes were incubated with various primary antibodies (and appropriate secondary antibodies). The image was resolved using an enhanced chemiluminescence system ECL (Thermo Scientific) and detected by autoradiography (Kodak). Rabbit anti-STING polyclonal antibody was developed in our laboratory as described previously (Ishikawa and Barber, 2008); other antibodies were obtained from following sources: β -actin (Sigma-Aldrich), p-IRF3 (Cell Signaling), IRF3 (Santa Cruz Biotechnology), p-p65 (Cell Signaling), p65 (Cell Signaling), p-TBK1 (Cell Signaling), TBK1 (Abcam), and cGAS (Cell Signaling).

Interferon- β ELISA Analysis

IFN- β ELISA was performed using either the IFN- β human ELISA kit from Invitrogen or the human IFN- β ELISA kit from PBL InterferonSource following the manufacturer's protocol.

Immunofluorescence Microscopy

Cell were fixed with 4% paraformaldehyde for 15 min in at 37°C and permeabilized with 0.05% Triton X-100 for 5 min at room temperature. Immunostain-

ing was performed with STING, IRF3, or p65 antibody followed by fluorescence-conjugated secondary antibodies (FITC goat anti-rabbit) (Invitrogen). Images were taken with a Leica LSM confocal microscope at the Image Core Facility, University of Miami.

Microarray Analysis

Total RNA was isolated from cells or tissues with the RNeasy Mini kit (QIAGEN). RNA quality was analyzed using a Bionalyzer RNA 6000 Nano (Agilent Technologies). Gene array analysis was examined by Illumina Sentrix BeadChip Array (Human HT-12_V4_Bead Chip) at the Oncogenomics Core Facility, University of Miami. Gene expression profiles were processed and statistical analysis was performed at the Bioinformatics Core Facility, University of Miami. Briefly, raw intensity values from Illumina array are uploaded on GeneSpring software from Agilent. Values are quantile normalized and log₂ transformed to the median of all samples. Significantly differential expressed genes from a two-class comparison are computed using the Student's t test and selected using threshold of p value ≤ 0.05 . Hierarchical clustering and visualization of selected differentially expressed genes is performed on GeneSpring using Pearson correlation distance method and linkage was computed using the Ward method. Fold-change analysis was performed between two groups, and differentially expressed genes were selected based on threshold of fold changes.

Real-Time qPCR

Total RNA was reverse transcribed using QuantiTect Reverse Transcription Kit (QIAGEN). Real-time PCR was performed with the TaqMan gene Expression Assay (Applied Biosystems).

Immunohistochemistry and Histological Analysis

Tissue microarray was purchased from Origene. Immunohistochemistry staining was performed with cGAS or STING antibody following standard protocol. The score for the extent of the IHC-stained area was set as 0 for no IHC signal at all, 1 for <10%, 2 for 10% to 50%, and 3 for >50% of tumor cells stained. The score for IHC intensity was also scaled as 0 for no IHC signal, 1 for weak, 2 for moderate, and 3 for strong. The final score used in the analysis was calculated by multiplying the extent score and intensity score, with a maximum score of 9. Staining was considered positive if scored ≥ 3 .

Virus Amplification, Purification, Titration, and Infection

HSV-1 γ 34.5 was kindly provided by Bernard Roizman. HSV-1 luc was kindly provided by David Leib. Vaccinia virus (vTF7-3) was kindly provided by John Rose. Virus was amplified in Vero cells and purified by sucrose-gradient ultracentrifugation following standard protocol. Plaque assay using serial diluted virus was performed in Vero cells following standard protocol. Cells were infected with virus at specific MOI for 1 hr, washed, and then incubated for designated period for specific assay examination.

RNA In Situ Hybridization

The STING and cGAS RNA probe was custom designed by ACD, and RNA in situ hybridization was performed using the RNAscope Multiplex Fluorescent Reagent Kit for cultured cells and the 2-plex RNAscope Reagent Kit for FFPE cells and tissue following the manufacturer's instructions. Staining quantification followed the score guideline, which was categorized into five grades: 0, no staining or <1 dot in every 10 cells (40 \times magnification); 1, 1–3 dots/cell (visible at 20–40 \times magnification); 2, 4–10 dots/cell and very few dot clusters (visible at 20–40 \times magnification); 3, >10 dots/cell and <10% positive cells have dot clusters (visible at 20 \times magnification); and 4, >10 dots per cell and >10% positive cells have dot clusters (visible at 20 \times magnification). Staining was considered positive if scored ≥ 1 .

Mouse Treatment

BALB/c nu/nu mice were purchased from Charles River and maintained in the institutional Division of Veterinary Resources (DVR). All experiments were performed with institutional animal care and use committee (IACUC) approval and in compliance with IACUC guidelines. Tumor cells were introduced in the flanks of BALB/c nude mice by subcutaneous injection of 2E6 of the appropriate tumor cells and tumors allowed to develop to an average diameter of

~0.5 cm. HSV1 γ 34.5 was then injected into the tumors every other day for a total of three times at the appropriate dosage (i.e., 50 μ l at 1E7 PFU/ml). PBS was used as vehicle control. Effects on tumor growth were monitored. Mice were euthanized when the tumor diameter exceeded 10 mm.

C57/BL6 wild-type (WT) or STING knockout (SKO) mice were injected subcutaneously with B16-OVA tumor cells (5E10⁵ cells/mouse) on day 0. On days 7, 9, and 11, mice were injected intratumorally with HSV1 γ 34.5 (5E5 PFU/mouse). PBS was used as control. Tumor volume was evaluated every other day.

Interferon- γ Assay

Splenocytes were isolated from WT or SKO mice inoculated with HSV1 γ 34.5 (5E5 PFU/mouse) on day 13 after B16-OVA cell inoculation. The cells were plated at 1E6 cells per well and stimulated with OVA peptide (SIINFEKL). After 48 hr, IFN- γ levels were determined from the supernatant using a mouse IFN- γ ELISA kit (R&D Systems) following the manufacturer's instruction.

Bisulfite Sequencing Analysis

Bisulfite conversion of genomic DNA was performed using the EZDNA methylation kit from Zymo Research followed by PCR amplification. PCR products were then gel purified and Sanger sequenced.

Genomic DNA Sequencing

Genomic DNA was extracted from CA and normal cells using the QIAGEN DNeasy kit, and the specific locus was sequenced by Polymorphic DNA Technologies.

Statistical Analysis

All statistical analysis was performed by Student's *t* test unless specified. The data were considered to be significantly different when *p* < 0.05.

ACCESSION NUMBERS

The accession number for the microarray data reported in this paper is GEO: GSE75205.

SUPPLEMENTAL INFORMATION

Supplemental Information includes eight figures and three tables and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2015.12.029>.

AUTHOR CONTRIBUTION

T.X. carried out most of the experiments; K.H. performed signaling immunoblot analysis; J.A. performed DNA damage signaling analysis; and G.N.B. wrote the manuscript.

ACKNOWLEDGMENTS

We thank Dr. Bijou Issac of the Sylvester Comprehensive Cancer Center Bioinformatics Core Facility for Gene expression array analysis, Ms. Delia Gutman and Ms. Auristela Rivera for mice breeding, and Dr. Phillip Ruiz of the Department of Surgery for IHC interpretation.

Received: July 8, 2015

Revised: October 28, 2015

Accepted: December 3, 2015

Published: December 31, 2015

REFERENCES

- Ahn, J., and Barber, G.N. (2014). Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. *Curr. Opin. Immunol.* 31, 121–126.
- Ahn, J., Gutman, D., Saijo, S., and Barber, G.N. (2012). STING manifests self DNA-dependent inflammatory disease. *Proc. Natl. Acad. Sci. USA* 109, 19386–19391.
- Ahn, J., Ruiz, P., and Barber, G.N. (2014a). Intrinsic self-DNA triggers inflammatory disease dependent on STING. *J. Immunol.* 193, 4634–4642.
- Ahn, J., Xia, T., Konno, H., Konno, K., Ruiz, P., and Barber, G.N. (2014b). Inflammation-driven carcinogenesis is mediated through STING. *Nat. Commun.* 5, 5166.
- Ahn, J., Konno, H., and Barber, G.N. (2015). Diverse roles of STING-dependent signaling on the development of cancer. *Oncogene* 34, 5302–5308.
- Arthur, J.C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J.M., Fan, T.J., Campbell, B.J., Abujamel, T., Dogan, B., Rogers, A.B., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 338, 120–123.
- Arthur, J.C., Gharaibeh, R.Z., Mühlbauer, M., Perez-Chanona, E., Uronis, J.M., McCafferty, J., Fodor, A.A., and Jobin, C. (2014). Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. *Nat. Commun.* 5, 4724.
- Barker, B.R., Taxman, D.J., and Ting, J.P. (2011). Cross-regulation between the IL-1 β /IL-18 processing inflammasome and other inflammatory cytokines. *Curr. Opin. Immunol.* 23, 591–597.
- Burdette, D.L., Monroe, K.M., Sotelo-Troha, K., Iwig, J.S., Eckert, B., Hyodo, M., Hayakawa, Y., and Vance, R.E. (2011). STING is a direct innate immune sensor of cyclic di-GMP. *Nature* 478, 515–518.
- Cai, X., Chiu, Y.H., and Chen, Z.J. (2014). The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. *Mol. Cell* 54, 289–296.
- Chatzinikolaou, G., Karakasiloti, I., and Garinis, G.A. (2014). DNA damage and innate immunity: links and trade-offs. *Trends Immunol.* 35, 429–435.
- Chen, J., and Huang, X.F. (2009). The signal pathways in azoxymethane-induced colon cancer and preventive implications. *Cancer Biol. Ther.* 8, 1313–1317.
- Corrales, L., Glickman, L.H., McWhirter, S.M., Kanne, D.B., Sivick, K.E., Katiyah, G.E., Woo, S.R., Lemmens, E., Banda, T., Leong, J.J., et al. (2015). Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. *Cell Rep.* 11, 1018–1030.
- Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.D., Mauceri, H., Beckett, M., Darga, T., et al. (2014). STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. *Immunity* 41, 843–852.
- DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., Alteri, R., Robbins, A.S., and Jemal, A. (2014). Cancer treatment and survivorship statistics, 2014. *CA Cancer J. Clin.* 64, 252–271.
- Dzutsev, A., Goldszmid, R.S., Viaud, S., Zitvogel, L., and Trinchieri, G. (2015). The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. *Eur. J. Immunol.* 45, 17–31.
- Elinav, E., Nowarski, R., Thaiss, C.A., Hu, B., Jin, C., and Flavell, R.A. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. *Nat. Rev. Cancer* 13, 759–771.
- Fearon, E.R. (2011). Molecular genetics of colorectal cancer. *Annu. Rev. Pathol.* 6, 479–507.
- Fu, J., Kanne, D.B., Leong, M., Glickman, L.H., McWhirter, S.M., Lemmens, E., Mechette, K., Leong, J.J., Lauer, P., Liu, W., et al. (2015). STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. *Sci. Transl. Med.* 7, 283ra52.
- Hammoud, S.S., Cairns, B.R., and Jones, D.A. (2013). Epigenetic regulation of colon cancer and intestinal stem cells. *Curr. Opin. Cell Biol.* 25, 177–183.
- Heiber, J.F., and Barber, G.N. (2012). Evaluation of innate immune signaling pathways in transformed cells. *Methods Mol. Biol.* 797, 217–238.
- Hornung, V., Hartmann, R., Ablasser, A., and Hopfner, K.P. (2014). OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. *Nat. Rev. Immunol.* 14, 521–528.
- Huber, S., Gagliani, N., Zenewicz, L.A., Huber, F.J., Bosurgi, L., Hu, B., Hedl, M., Zhang, W., O'Connor, W., Jr., Murphy, A.J., et al. (2012). IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. *Nature* 491, 259–263.

- Ishikawa, H., and Barber, G.N. (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* 455, 674–678.
- Ishikawa, H., Ma, Z., and Barber, G.N. (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature* 461, 788–792.
- Jin, B., and Robertson, K.D. (2013). DNA methyltransferases, DNA damage repair, and cancer. *Adv. Exp. Med. Biol.* 754, 3–29.
- Jin, L., Xu, L.G., Yang, I.V., Davidson, E.J., Schwartz, D.A., Wurfel, M.M., and Cambier, J.C. (2011). Identification and characterization of a loss-of-function human MPYS variant. *Genes Immun.* 12, 263–269.
- Kidane, D., Chae, W.J., Czocho, J., Eckert, K.A., Glazer, P.M., Bothwell, A.L., and Sweasy, J.B. (2014). Interplay between DNA repair and inflammation, and the link to cancer. *Crit. Rev. Biochem. Mol. Biol.* 49, 116–139.
- Kim, E.R., and Chang, D.K. (2014). Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. *World J. Gastroenterol.* 20, 9872–9881.
- Kolodkin-Gal, D., Edden, Y., Hartshtark, Z., Ilan, L., Khalaileh, A., Pikarsky, A.J., Pikarsky, E., Rabkin, S.D., Panet, A., and Zamir, G. (2009). Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. *Gene Ther.* 16, 905–915.
- Kondo, T., Kobayashi, J., Saitoh, T., Maruyama, K., Ishii, K.J., Barber, G.N., Komatsu, K., Akira, S., and Kawai, T. (2013). DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. *Proc. Natl. Acad. Sci. USA* 110, 2969–2974.
- Konno, H., Konno, K., and Barber, G.N. (2013). Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. *Cell* 155, 688–698.
- Lao, V.V., and Grady, W.M. (2011). Epigenetics and colorectal cancer. *Nat. Rev. Gastroenterol. Hepatol.* 8, 686–700.
- Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. *N. Engl. J. Med.* 372, 2509–2520.
- Lord, C.J., and Ashworth, A. (2012). The DNA damage response and cancer therapy. *Nature* 481, 287–294.
- Louis, P., Hold, G.L., and Flint, H.J. (2014). The gut microbiota, bacterial metabolites and colorectal cancer. *Nat. Rev. Microbiol.* 12, 661–672.
- Mitchell, S.M., Ross, J.P., Drew, H.R., Ho, T., Brown, G.S., Saunders, N.F., Duesing, K.R., Buckley, M.J., Dunne, R., Beetson, I., et al. (2014). A panel of genes methylated with high frequency in colorectal cancer. *BMC Cancer* 14, 54.
- Rowe, J., and Cen, P. (2014). TroVax in colorectal cancer. *Hum. Vaccin. Immunother.* 10, 3196–3200.
- Salcedo, R., Worschech, A., Cardone, M., Jones, Y., Gyulai, Z., Dai, R.M., Wang, E., Ma, W., Haines, D., O’Hugin, C., et al. (2010). MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. *J. Exp. Med.* 207, 1625–1636.
- Salcedo, R., Cataisson, C., Hasan, U., Yuspa, S.H., and Trinchieri, G. (2013). MyD88 and its divergent toll in carcinogenesis. *Trends Immunol.* 34, 379–389.
- Sosa, V., Moliné, T., Somoza, R., Paciucci, R., Kondoh, H., and LLeonart, M.E. (2013). Oxidative stress and cancer: an overview. *Ageing Res. Rev.* 12, 376–390.
- Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z.J. (2013). Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* 339, 786–791.
- Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung, M.Y., Duggan, R., Wang, Y., Barber, G.N., Fitzgerald, K.A., et al. (2014). STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. *Immunity* 41, 830–842.
- Woo, S.R., Corrales, L., and Gajewski, T.F. (2015). The STING pathway and the T cell-inflamed tumor microenvironment. *Trends Immunol.* 36, 250–256.
- Wu, J.S. (2007). Rectal cancer staging. *Clin. Colon Rectal Surg.* 20, 148–157.
- Yarbrough, M.L., Zhang, K., Sakthivel, R., Forst, C.V., Posner, B.A., Barber, G.N., White, M.A., and Fontoura, B.M. (2014). Primate-specific miR-576-3p sets host defense signalling threshold. *Nat. Commun.* 5, 4963.
- Yi, G., Brendel, V.P., Shu, C., Li, P., Palanathan, S., and Cheng Kao, C. (2013). Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. *PLoS ONE* 8, e77846.
- Zhu, Q., Man, S.M., Gurung, P., Liu, Z., Vogel, P., Lamkanfi, M., and Kanne-ganti, T.D. (2014). Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. *J. Immunol.* 193, 4779–4782.
- Zitvogel, L., Galluzzi, L., Smyth, M.J., and Kroemer, G. (2013). Mechanism of action of conventional and targeted anticancer therapies: reinstating immuno-surveillance. *Immunity* 39, 74–88.